The CHARM program consisted of 3 component trials, each comparing candesartan with placebo in a distinct population of patients with symptomatic heart failure [9]: CHARM-Alternative: patients with ...
A substudy of the CHARM trial (see Trial Glossary below for expansion of all trial names mentioned in this article) has shown that the angiotensin receptor blocker (ARB) candesartan reduces the risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results